A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer

Basal-like breast cancer is a molecular subtype of breast cancer with a poor prognosis. Follow-up studies of long-term outcome in these patients, demonstrates they can be separated into two clinical groups: those who succumb to their disease within the first 5 years and those expected to show excellent long term survival. Currently available clinical/histopathological variables as well as molecular signatures show little capacity to identify basal breast cancer patients with either a high or low risk of disease relapse. Using data derived from 85 basal-like breast cancer patients, we identified a 14-gene signature, which we subsequently validated on an additional 49 basal breast cancer patient set. The ability to distinguish between these two sub-groups of basal breast cancer patients at the time of initial diagnosis would permit tailoring aggressive therapeutic regimens to those patients with a poor prognosis and conversely avoid such therapy in low risk patients.

• Publication year

  2012

• Venue

  Scientific Reports

• Publication date

  2012-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/srep00227PMID 22355741PMCID 3259129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

  2011cited by this paper
• Kinome expression profiling and prognosis of basal breast cancers

  2011cited by this paper
• Triple-negative breast cancer: an unmet medical need.

  2011cited by this paper
• E2F1 and KIAA0191 expression predicts breast cancer patient survival

  2011cited by this paper
• Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

  2010cited by this paper
• A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

  2010cited by this paper
• Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

  2010cited by this paper
• Frozen robust multiarray analysis (fRMA).

  2010cited by this paper
• An algorithm to discover gene signatures with predictive potential

  2010cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

  2009cited by this paper
• Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.

  2009cited by this paper
• TDRD3, a novel Tudor domain-containing protein, localizes to cytoplasmic stress granules

  2008cited by this paper
• Ins and outs of ADF/cofilin activity and regulation.

  2008cited by this paper
• Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?

  2008cited by this paper
• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  2008cited by this paper
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cited by this paper
• Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

  2008cited by this paper
• Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort

  2008cited by this paper
• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  2007cited by this paper
• Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

  2007cited by this paper
• Adjusting batch effects in microarray expression data using empirical Bayes methods.

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

  2007cited by this paper
• The cofilin pathway in breast cancer invasion and metastasis

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

  2007cited by this paper
• Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity

  2007cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

  2006cited by this paper
• The proteasome and proteasome inhibitors in cancer therapy.

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?

  2004cited by this paper
• Expression profiling to predict postoperative prognosis for estrogen receptor‐negative breast cancers by analysis of 25,344 genes on a cDNA microarray

  2004cited by this paper
• Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.

  1998cited by this paper
• Lessons from the first decade.

  1980cited by this paper
• Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up.

  1977cited by this paper

• Efficacy of sacituzumab govitecan in triple-negative breast cancer with hepatic visceral crisis: a case report

  2026cites this paper
• Dogs as a Model for Cancer: An Update.

  2026cites this paper
• Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy.

  2026cites this paper
• Preliminary study on targeted therapy of breast cancer using tumor cell membrane-coated dual-loaded liposomes based on chemo-photothermal synergistic effects.

  2025cites this paper
• Dual metabolic targeting liposomes potentiate triple-negative breast cancer radiosensitivity via glucose and glutathione starvation.

  2025cites this paper
• Arginine methylation-dependent METTL14-SMN interaction regulates RNA m6A homeostasis

  2025cites this paper
• Antitumour activity of violacein in osteosarcoma, neuroblastoma and triple-negative breast cancer spheroids.

  2025cites this paper
• Paclitaxel loaded mitochondrial targeting virus mimicking polymeric nanosystem for tackling triple-negative breast cancer

  2025cites this paper
• Assessing the recurrence rate in locally advanced Luminal A patients compared to triple-negative patients in Shahid Rahimi Hospital Khorramabad in 2022: a cross-sectional study

  2025cites this paper
• Penetrative biomimetic nanovehicle boosts immunotherapy in triple-negative breast cancer via SOS1 blockade

  2025cites this paper
• PD-1/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: synergistic mechanisms and research progress.

  2025cites this paper
• Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism

  2025cites this paper
• Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer

  2025cites this paper
• Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study

  2025cites this paper
• The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study

  2025cites this paper
• Cancer‐Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple‐Negative Breast Cancer via the Activation of Cancer‐Associated Fibroblasts

  2025cites this paper
• Study on the diversity and difference of intratumoral flora in patients with triple negative breast cancer

  2025cites this paper
• The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer

  2025influential citation
• Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation

  2025cites this paper
• Fibromatosis-like metaplastic carcinoma with aggressive metastasis and a TERT promoter mutation: a case report and literature review

  2025cites this paper
• Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection

  2024cites this paper
• Soluble TREM2 drives triple-negative breast cancer progression via activation of the AKT pathway.

  2024cites this paper
• Sterile Alpha Motif Domain-Containing 5 Suppresses Malignant Phenotypes and Tumor Growth in Breast Cancer: Regulation of Polo-Like Kinase 1 and c-Myc Signaling in a Xenograft Model

  2024cites this paper
• Advances in Diagnosis, Molecular Typing, and Treatment of Triple-Negative Breast Cancer

  2024cites this paper
• Identification of the metabolic protein ATP5MF as a potential therapeutic target of TNBC

  2024cites this paper
• Establishment of prognostic model for invasive ductal carcinoma with distant metastasis within the triple-negative breast cancer: a SEER population-based study.

  2024cites this paper
• Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinoma

  2024cites this paper
• Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer

  2024cites this paper
• Ultrasound-based comparative analysis and nomogram development for predicting triple-negative and non-triple-negative breast cancer: a 4-year institutional study in Quanzhou First Hospital

  2024cites this paper
• Integrative multi-omics analysis reveals ortho-topolin riboside exhibits anticancer activity by regulating metabolic pathways in radio-resistant triple negative breast cancer cells.

  2024cites this paper
• Application of nanoparticles in breast cancer treatment: a systematic review

  2024cites this paper
• Coiled-Coil Protein Hydrogels Engineered with Minimized Fiber Diameters for Sustained Release of Doxorubicin in Triple-Negative Breast Cancer

  2024cites this paper
• Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

  2024cites this paper
• Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer

  2024cites this paper
• Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with Triple-Negative Breast Cancer

  2024cites this paper
• ΔNp63 regulates MDSC survival and metabolism in triple-negative breast cancer

  2024cites this paper
• From dietary lignans to cancer therapy: Integrative systems analysis of enterolactone's molecular targets and signaling pathways in combatting cancer stem cells in triple-negative breast cancer

  2024cites this paper
• Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality

  2023cites this paper
• The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells

  2023cites this paper
• Myosin 1e deficiency affects migration of 4T1 breast cancer cells

  2023cites this paper
• NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.

  2023cites this paper
• Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer

  2023cites this paper
• Synchronous Occurrence of Triple-Negative Breast Cancer and Malignant Melanoma

  2023influential citation
• Crystal structure of Tudor domain of TDRD3 in complex with a small molecule antagonist.

  2023cites this paper
• Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer

  2023cites this paper
• Towards a potential pan-cancer prognostic signature for gene expression based on probesets and ensemble machine learning

  2022influential citation
• Loss of Myosin-1e biases MMTV-PyMT induced breast cancer towards a differentiated and secretory state

  2022cites this paper
• Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment.

  2022cites this paper
• Recent advances in therapeutic strategies for triple-negative breast cancer

  2022cites this paper
• A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors

  2021cites this paper
• YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer

  2021cites this paper
• An overview of breast cancer: Classification and related signaling pathways

  2021cites this paper
• Establishment and Validation of a Comprehensive Prognostic Model for Patients With HNSCC Metastasis

  2021cites this paper
• Analyzing mRNAsi-Related Genes Identifies Novel Prognostic Markers and Potential Drug Combination for Patients with Basal Breast Cancer

  2021cites this paper
• Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer

  2021cites this paper
• A meta-analysis of the inhibin network reveals prognostic value in multiple solid tumors

  2020cites this paper
• Myosins and Disease.

  2020cites this paper
• Long-Tailed Unconventional Class I Myosins in Health and Disease

  2020cites this paper
• A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patients

  2020cites this paper
• Cytoskeletal Remodeling in Cancer

  2020cites this paper
• Myosins: Driving us towards novel targets and biomarkers in cancer.

  2020cites this paper
• Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer

  2020cites this paper
• Reciprocal transrepression between FOXF2 and FOXQ1 controls basal‐like breast cancer aggressiveness

  2019cites this paper
• Roles of Myosin-Mediated Membrane Trafficking in TGF-β Signaling

  2019cites this paper
• Tail domains of myosin-1e regulate phosphatidylinositol signaling and F-actin polymerization at the ventral layer of podosomes

  2019cites this paper
• Molecular Classification and Prognostic Signatures of Breast Tumors

  2019cites this paper
• Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance

  2018cites this paper
• BMI1 is a therapeutic target in recurrent medulloblastoma

  2018cites this paper
• Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response

  2018cites this paper
• Bone Metastasis in Advanced Breast Cancer: Analysis of Gene Expression Microarray

  2018cites this paper
• Increased α-actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer

  2018cites this paper
• Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer

  2018cites this paper
• Breast cancer intrinsic subtypes: a critical conception in bioinformatics

  2017cites this paper
• Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer

  2017cites this paper
• Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells

  2017cites this paper
• Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

  2017influential citation
• ERBB2 as a driver of an invasive phenotype of cells grown in 3D culture and an important regulator of oncogenic miRNAs' expression in breast cancer

  2017cites this paper
• Dogs as a Model for Cancer.

  2016cites this paper
• Myosin 1e promotes breast cancer malignancy by enhancing tumor cell proliferation and stimulating tumor cell de-differentiation

  2016influential citation
• Induction Chemotherapy for Breast Cancer

  2016cites this paper
• The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

  2016cites this paper
• Transcript signatures that predict outcome and identify targetable pathways in MYCN‐amplified neuroblastoma

  2016cites this paper
• Do myosins contribute to metastasis of prostate cancer cells

  2015cites this paper
• Pyrvinium Targets CD 133 in Human Glioblastoma Brain Tumor – Initiating Cells

  2015cites this paper
• Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

  2015cites this paper
• LRIG1 opposes epithelial to mesenchymal transition and inhibits invasion of basal-like breast cancer cells

  2015cites this paper
• Delineating cellular heterogeneity and organization of breast cancer stem cells

  2015cites this paper
• Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells

  2015cites this paper
• Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach

  2015cites this paper
• Identification and evaluation of network modules for the prognosis of basal-like breast cancer

  2015cites this paper
• Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status

  2014cites this paper
• A program to identify prognostic and predictive gene signatures

  2014cites this paper
• Non‐muscle myosins in tumor progression, cancer cell invasion, and metastasis

  2014cites this paper
• Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice

  2014cites this paper
• Breast tumor subgroups reveal diverse clinical prognostic power

  2014cites this paper
• Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer

  2014cites this paper
• Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K

  2014influential citation
• Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response*

  2014cites this paper
• A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status

  2014influential citation
• A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients

  2014cites this paper